Eileen O'Reilly, MD
There are several novel therapeutic approaches under investigation for the treatment of patients with pancreatic cancer. Immunotherapy, for example, has become an area of excitement, with early combination studies showing activity in these tumors.
on Gastrointestinal Cancers, Eileen O’Reilly, MD, associate director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, discussed novel therapeutic approaches for the treatment of patients with pancreatic cancer.
OncLive: Can you give an overview of your presentation on pancreatic cancer?
The initial part of my discussion was to review where we are with the current state-of-the-art frontline therapies for good performance status patients [treated] with FOLFIRINOX, gemcitabine, and nab-paclitaxel. There was a brief discussion of beyond frontline therapy with the relatively recent data of liposomal irinotecan [Onivyde] and fluorouracil.
... to read the full story